Division of Gastroenterology and Hepatology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Liver Research Center, Pittsburgh, Pennsylvania, USA.
Am J Gastroenterol. 2018 Feb;113(2):175-194. doi: 10.1038/ajg.2017.469. Epub 2018 Jan 16.
Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month. Corticosteroids provide short-term survival benefit in about half of treated patients with severe AH and long-term mortality is related to severity of underlying liver disease and is dependent on abstinence from alcohol. General measures in patients hospitalized with ALD include inpatient management of liver disease complications, management of alcohol withdrawal syndrome, surveillance for infections and early effective antibiotic therapy, nutritional supplementation, and treatment of the underlying alcohol-use disorder. Liver transplantation, a definitive treatment option in patients with advanced alcoholic cirrhosis, may also be considered in selected patients with AH cases, who do not respond to medical therapy. There is a clinical unmet need to develop more effective and safer therapies for patients with ALD.
酒精性肝病(ALD)包括一系列临床病理表现,包括脂肪肝、酒精性肝炎(AH)和肝硬化及其并发症。大多数患者在晚期被诊断出来,关于早期疾病患者的患病率和特征的数据有限。ALD 的诊断需要记录慢性大量饮酒,并排除其他肝病的原因。长期戒酒是预防疾病进展最有效的策略。AH 的表现为黄疸迅速出现或加重,在严重情况下,可能会发展为慢性肝衰竭急性加重,此时死亡率取决于肝外器官衰竭的数量,在 1 个月时可能高达 20-50%。皮质类固醇在大约一半接受严重 AH 治疗的患者中提供短期生存获益,长期死亡率与潜在肝病的严重程度有关,并取决于是否戒酒。ALD 住院患者的一般治疗措施包括住院管理肝病并发症、酒精戒断综合征的管理、感染和早期有效抗生素治疗的监测、营养补充以及潜在酒精使用障碍的治疗。肝移植是晚期酒精性肝硬化患者的一种确定性治疗选择,对于那些对药物治疗无反应的 AH 患者,也可能会被考虑。对于 ALD 患者,需要开发更有效和更安全的治疗方法来满足临床需求。